NCT00001587View on ClinicalTrials.gov

A Phase I Study of Isolated Hepatic Portal and Arterial Perfusion (IHP) With Escalating Dose Melphalan for Primary or Metastatic Unresectable Cancers of the Liver

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

September 30, 1997

Study Completion Date

March 31, 2001

Conditions
Liver NeoplasmsNeoplasm Metastasis
Interventions
PROCEDURE

Isolated hepatic portal and arterial perfusion

DRUG

Melphalan

Trial Locations (1)

20892

National Cancer Institute (NCI), Bethesda

All Listed Sponsors
lead

National Cancer Institute (NCI)

NIH